Phase 1/2 Study of Valproic Acid and Short-course Radiotherapy Plus Capecitabine as preoperative Treatment in Low-moderate Risk Rectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Valproic acid (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms V-shoRT-R3
- 31 Aug 2018 Biomarkers information updated
- 28 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018.
- 28 Mar 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2017.